Pharmaceutical News

RSS

FDA approval for Diovan (Valsartan)

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Diovan (valsartan), the most prescribed ARB (angiotensin receptor blocker) in the US and worldwide, for a new indication to reduce cardiovascular death in patients at high risk (with left ventricular failure or left ventricular dysfunction) following a heart attack.

4 Aug 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

Mixing slow-release painkillers with alcohol - potentially deadly

Health Canada has issued a warning that mixing some slow-release painkillers with alcohol could be potentially deadly.

4 Aug 2005

Pfizer adds warning to Celebrex arthritis drug

Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.

3 Aug 2005

Living Cell Technologies announces results for treating Huntington's disease

Living Cell Technologies announced pre-clinical results today showing its brain protection product, NeurotrophinCell (NtCell) produces a marked reduction in the size of brain lesions in a Huntington's disease (HD) model.

2 Aug 2005

MediciNova starts phase II clinical trial of MN-166 for multiple sclerosis

MediciNova today announced the enrollment of patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. MN-166 is an orally administered drug with a novel mechanism of action that includes the inhibition of phosphodiesterase IV.

2 Aug 2005

Heparinase I is not a suitable replacement for protamine

The results of an international clinical trial led by Duke University Medical Center researchers has shown that a new drug is not a suitable replacement for protamine, a drug that has been used for more than 40 years after coronary artery bypass surgery to return thinned blood to its normal state.

1 Aug 2005

FDA bans antibiotic use for poultry

The U.S. Food and Drug Administration (FDA) has banned the use of a poultry antibiotic made by Bayer.

31 Jul 2005

Law to restrict cold medicines well on it's way

A bill that would limit access to common cold medicines containing pseudoephedrine, an ingredient that can be used to make the highly addictive drug methamphetamine, has been unanimously approved by the Senate judiciary committee.

29 Jul 2005

Ranbaxy receives tentative approval to manufacture and market Glimepiride tablets

Indian drug manufacturer, Ranbaxy Pharmaceuticals has tentative approval from the U.S. Food and Drug Administration to manufacture and market Glimepiride Tablets, 3 mg and 6 mg.

28 Jul 2005

Pharmaceutical direct-to-consumer to evolve holistically

Restrictions against using brand names have rendered pharmaceutical Direct-to-Consumer Advertising (DTCA) in Europe an informative rather than promotional exercise. DTCA is now broadening its scope, evolving from its narrow publicity orientation to a more comprehensive approach focused on improved patient outcomes and value addition.

27 Jul 2005

Biota's potential damages claim against GlaxoSmithKline could be as high as $430 million

Biota Holdings Limited of Melbourne, Australia, has announced its Particulars of Loss and Damage in its suit against GlaxoSmithKline (GSK) for failing to support Biota’s influenza drug, Relenza. The damages assessment was filed with the Victorian Supreme Court and estimates Biota’s losses in the range of $308 million to $430 million.

26 Jul 2005

TEVA to acquire IVAX for $7.4 billion

TEVA Pharmaceutical Industries and IVAX Corporation have jointly announced that they have signed a definitive agreement providing for the acquisition of IVAX by TEVA.

26 Jul 2005

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

26 Jul 2005

Government in Ontario will pay for three new cancer drugs

Canadian Health Minister George Smitherman has announced that the government will add three new and expensive cancer-fighting drugs to the list of medications it funds.

25 Jul 2005

Breast cancer drug Herceptin soon to be widely available on NHS

The British health secretary Patricia Hewitt has ordered a fast-track assessment of Herceptin, a drug which has shown great promise in treating the early stages of breast cancer.

23 Jul 2005

Provectus to begin clinical trials of new cancer treatment, PV-10

Provectus Pharmaceuticals announced today that it has obtained final clearance to begin the first Phase 1 clinical trial of PV-10, the Company's lead cancer treatment.

21 Jul 2005

ev3 announces FDA approval of treatment for brain vascular disorder

ev3 today announced that its majority-owned subsidiary Micro Therapeutics has received pre-market application (PMA) approval from the U.S. Food and Drug Administration (FDA) to commercialize its Onyx Liquid Embolic System (Onyx) for the treatment of arterio-venous malformations (AVMs), a vascular disorder in the brain.

21 Jul 2005

Sale of abortion-pill threatened by U.S. lawmakers

The U.S. Food and Drug Administration (FDA) has issued a new warning this week regarding the abortion pill RU-486 following the deaths of five women taking it, from bacterial infections.

21 Jul 2005

UK medical watchdog wants more proof on value of Alzheimer's drugs

In the UK the country's watchdog for cost-effectiveness in medical treatments, the National Institute for Health and Clinical Excellence (NICE), has asked drug makers for more evidence about the benefits of their Alzheimer's medicines.

21 Jul 2005